Macron and the moguls: Inside the fight over a 'French Fox News'
Behind the corporate battle for French media company Lagardere, there's a political tug-of-war involving the country's richest man, a media magnate and President Emmanuel Macron.
Behind the corporate battle for French media company Lagardere, there's a political tug-of-war involving the country's richest man, a media magnate and President Emmanuel Macron.
British broadband company TalkTalk said on Thursday it has agreed a 1.1 billion-pound ($1.5 billion) takeover by shareholder Toscafund and private-equity investor Penta.
Indonesian motorbike driver unions for ride-hailing and food delivery firms Grab and Gojek say they will kick off protests across the country if merger talks between the firms proceed without them, fearing it could result in mass job losses.
Video games maker Electronic Arts said on Monday it had reached an agreement to buy Codemasters in a deal worth $1.2 billion, trumping an earlier agreement between the British company and rival Take-Two Interactive Software.
Social network firm Reddit said https://redditblog.com/2020/12/13/reddit-welcomes-video-platform-dubsmash-to-team on Sunday it would buy short-video platform Dubsmash, becoming the latest company to expand in a space dominated by Chinese-owned TikTok.
U.S.-based investment group MSP Sports Capital is taking a significant minority stake in McLaren Racing in a deal the Formula One team said would give them the tools to return to the top of the sport.
China Molybdenum Co said on Sunday it had acquired a 95% stake in the Kisanfu copper-cobalt mine in the Democratic Republic of Congo (DRC) from U.S.-based Freeport-McMoRan Inc for $550 million.
Japan's Hitachi Ltd plans to sell a 60% stake in its overseas home appliance business to Turkish consumer electronics maker Arcelik AS for about $300 million, and jointly operate the business, the Nikkei newspaper said on Sunday.
Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.